Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
239.3 USD | +2.89% | +3.37% | +1.59% |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The firm trades with high earnings multiples: 28.7 times its 2024 earnings per share.
- The company's enterprise value to sales, at 3.3 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.62% | 11.94B | C+ | ||
-0.02% | 42.11B | B | ||
+46.23% | 40.08B | A | ||
+5.04% | 40B | B- | ||
-11.32% | 26.87B | C | ||
+5.25% | 24.58B | B- | ||
-23.83% | 18.44B | B | ||
+22.75% | 11.66B | C+ | ||
+6.44% | 11.01B | B+ | ||
-18.61% | 9.87B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CRL Stock
- Ratings Charles River Laboratories International, Inc.